Advaxis To Webcast Investor & Analyst Day 2017

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that its annual Investor & Analyst Day, scheduled for Monday, June 12, 2017 at 1:00 p.m., will be webcast live.

To access the live webcast, remote individuals can visit www.event.webcasts.com. Full contact information and company affiliation are required to access the webcast. For those interested in attending in-person in New York City, please register online. The presentation program and agenda is now available at the same link, and full presentation slides and audio will be available for viewing on Tuesday, June 13.

At the event, presentations will focus on Patients, Partnerships and Progress, providing updates on the company’s Lm Technology™ and nine development programs. Clinical investigators sharing their experiences and case studies during this year’s event include:

• Sharad Ghamande, MD, an associate professor and Director of Gynecologic Oncology at the Georgia Cancer Center at Augusta University, who is a principal investigator in Advaxis’ Phase 1 study of axalimogene filolisbac evaluated at higher doses in women with metastatic cervical cancer.
• Cathy Eng, MD, FACP, who is a professor and the Associate Medical Director, Colorectal Center, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Dr. Eng is the principal investigator in Advaxis’ Phase 2 FAWCETT study, evaluating axalimogene filolisbac in patients with metastatic anal cancer.
• Nicola Mason, PhD, BVetMed, an associate professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine, specializing in canine cancer, is an investigator evaluating ADXS-HER2 in dogs with surgically treated osteosarcoma.
• Brian Slomovitz, MD, who is the Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Miami Miller School of Medicine, as well as Co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center. Dr. Slomovitz is a co-principal investigator on the company’s Phase 3 AIM2CERV trial in high-risk, locally advanced cervical cancer and an investigator evaluating axalimogene filolisbac in combination with AstraZeneca’s durvalumab in metastatic cervical cancer.
• Mark Stein, MD, a medical oncologist at the Rutgers Cancer Institute of New Jersey, working across multiple disciplines in the Prostate Cancer Program and the Urologic Oncology Program, is an investigator in a Phase 1/2 trial evaluating ADXS-PSA in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).

Advaxis senior management will also share details on the company’s clinical development, the collaboration with Amgen, Inc. on ADXS-NEO and plans for regulatory submission and commercialization. Advaxis presentations include:

• Robert Petit, PhD, discussing axalimogene filolisbac and a potential prognostic biomarker, and preclinical work with Lm-WT1, ADXS-NEO and ADXS-HOT
• Mayo Pujols, discussing details of the IND for ADXS-NEO
• Fatima Ahmad, PharmD, sharing a publication and congress overview
• Bob Ashworth, PhD, providing a EU regulatory approval update
• Chris Duke presenting Advaxis’ plan for EU commercial readiness

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a late-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology™ immunotherapies axalimogene filolisbac and ADXS-DUAL target HPV-associated cancers and are in clinical trials for four potential indications, including Phase 3 in invasive cervical cancer and metastatic cervical cancer in combination with nivolumab, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies, axalimogene filolisbac and ADXS-DUAL. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.

You are cautioned not to place undue reliance on any forward-looking statements.